Hanmi Group Increases Cash Dividends Following Record Earnings
Hanmi Pharmaceutical Group announced an expansion of cash dividends to enhance shareholder value, driven by record performances from its affiliates. The cash dividend amounts include 300 KRW per common share of Hanmi Science (0.79% yield), 2,000 KRW per common share of Hanmi Pharmaceutical (0.40% yield), and 650 KRW per common share of JVM (2.5% yield). The plan will be finalized at upcoming shareholders' meetings. Hanmi Group aims for combined sales of 5 trillion KRW by 2030, focusing on four core areas: obesity, anti-aging, digital healthcare, and robotics.
Theia Market Signal Identification - AI Assisted
Hanmi Pharmaceutical Group will expand cash dividends to enhance shareholder value, with record earnings from affiliates. Dividends will be 300 KRW per common share of Hanmi Science (0.79% yield), 2,000 KRW for Hanmi Pharmaceutical (0.40% yield), and 650 KRW for JVM (2.5% yield), pending approval at shareholder meetings.
The company aims to return a percentage of net profit to shareholders, targeting over 30% for Hanmi Science and over 20% for the others. By 2030, Hanmi Group seeks combined sales of 5 trillion KRW, focusing on obesity, anti-aging, digital healthcare, and robotics. The strategy includes expanding high-value businesses and achieving significant operating profit margins.
Comments